JP2023504748A5 - - Google Patents

Info

Publication number
JP2023504748A5
JP2023504748A5 JP2022534224A JP2022534224A JP2023504748A5 JP 2023504748 A5 JP2023504748 A5 JP 2023504748A5 JP 2022534224 A JP2022534224 A JP 2022534224A JP 2022534224 A JP2022534224 A JP 2022534224A JP 2023504748 A5 JP2023504748 A5 JP 2023504748A5
Authority
JP
Japan
Prior art keywords
approximately
liquid pharmaceutical
pharmaceutical preparation
preparation according
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022534224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504748A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063620 external-priority patent/WO2021118930A2/en
Publication of JP2023504748A publication Critical patent/JP2023504748A/ja
Publication of JP2023504748A5 publication Critical patent/JP2023504748A5/ja
Priority to JP2025152037A priority Critical patent/JP2026009902A/ja
Withdrawn legal-status Critical Current

Links

JP2022534224A 2019-12-09 2020-12-07 抗pd-l1抗体製剤 Withdrawn JP2023504748A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025152037A JP2026009902A (ja) 2019-12-09 2025-09-12 抗pd-l1抗体製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945730P 2019-12-09 2019-12-09
US62/945,730 2019-12-09
PCT/US2020/063620 WO2021118930A2 (en) 2019-12-09 2020-12-07 Anti-pd-l1 antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025152037A Division JP2026009902A (ja) 2019-12-09 2025-09-12 抗pd-l1抗体製剤

Publications (2)

Publication Number Publication Date
JP2023504748A JP2023504748A (ja) 2023-02-06
JP2023504748A5 true JP2023504748A5 (cg-RX-API-DMAC7.html) 2023-12-14

Family

ID=74206149

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022534224A Withdrawn JP2023504748A (ja) 2019-12-09 2020-12-07 抗pd-l1抗体製剤
JP2025152037A Pending JP2026009902A (ja) 2019-12-09 2025-09-12 抗pd-l1抗体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025152037A Pending JP2026009902A (ja) 2019-12-09 2025-09-12 抗pd-l1抗体製剤

Country Status (15)

Country Link
US (1) US20230039268A1 (cg-RX-API-DMAC7.html)
EP (1) EP4073120A2 (cg-RX-API-DMAC7.html)
JP (2) JP2023504748A (cg-RX-API-DMAC7.html)
KR (1) KR20220113414A (cg-RX-API-DMAC7.html)
CN (1) CN114787191A (cg-RX-API-DMAC7.html)
AU (1) AU2020399619A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011228A2 (cg-RX-API-DMAC7.html)
CA (1) CA3158987A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022001486A1 (cg-RX-API-DMAC7.html)
CR (1) CR20220322A (cg-RX-API-DMAC7.html)
IL (1) IL293580A (cg-RX-API-DMAC7.html)
MX (1) MX2022006784A (cg-RX-API-DMAC7.html)
PE (1) PE20221281A1 (cg-RX-API-DMAC7.html)
TW (1) TWI886185B (cg-RX-API-DMAC7.html)
WO (1) WO2021118930A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
MX2024007749A (es) 2021-12-22 2024-07-01 Genentech Inc Formulaciones clinicas de anticuerpos anti-tigit.
WO2024126750A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Methods for treating cancer
JP2026508415A (ja) * 2023-03-08 2026-03-10 イムノバント サイエンシズ ゲーエムベーハー ポリソルベート賦形剤を含む高濃度タンパク質製剤およびその製造方法
WO2025085404A1 (en) 2023-10-16 2025-04-24 Genentech, Inc. Diagnostic and therapeutic methods for treating lung cancer
WO2026158433A1 (zh) * 2025-01-24 2026-07-30 江苏恒瑞医药股份有限公司 一种包含抗pd-l1抗体的药物组合物及其医药用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
DK3049441T3 (da) * 2013-09-27 2020-02-03 Hoffmann La Roche Anti-PDL1-antistofformuleringer
DK3570884T3 (da) * 2017-01-17 2020-11-30 Genentech Inc Subkutane HER2-antistofformuleringer

Similar Documents

Publication Publication Date Title
JP2016533335A5 (cg-RX-API-DMAC7.html)
TWI829799B (zh) 一種TGF-β受體融合蛋白醫藥組成物及其用途
JP6967515B2 (ja) Pd−1抗体
JP2019047807A (ja) Pdgf受容体ベータ結合ポリペプチド
US12565526B2 (en) Formulations of anti-RSV antibodies and methods of use thereof
CN112741804A (zh) 含有抗pd-l1抗体的稳定制剂
TW202615095A (zh) 抗rsv單株抗體配製物
CN110732023B (zh) 一种her2抗体药物组合物及其用途
JP2011137002A (ja) 組換えil−9抗体およびその使用
TWI865727B (zh) 一種抗il-4r抗體醫藥組成物及其用途
CN115867316B (zh) 抗pd-1抗体药物组合物及其用途
ES2699078T3 (es) Proteínas de unión a antigeno específicas para componente amiloide sérico P
JP2023507795A5 (cg-RX-API-DMAC7.html)
CN113507938A (zh) 包含抗il-5抗体的药物组合物及其用途
CN110960490A (zh) 一种抗egfr抗体偶联药物组合物及其用途
JP2025500483A5 (cg-RX-API-DMAC7.html)
TW202144005A (zh) 一種抗ox40抗體醫藥組成物及其用途
JP2024529377A (ja) 抗angptl3抗体又はその抗原結合断片の医薬組成物及びその使用
JP2022513671A (ja) Cd40抗体医薬品組成物およびその使用
CA3115708C (en) Formulations of anti-rsv antibodies and methods of use thereof
HK40069022A (en) Stable and highly concentrated formulation of the antibody nimotuzumab
CN114867468A (zh) 尼妥珠单抗的稳定和高浓度制剂
AU2023391877A1 (en) Recombinant antibody, pharmaceutical composition comprising the same, and uses thereof in treating cancers
TW202241505A (zh) 抗il-17抗體治療自體免疫性疾病和炎症的方法
JP2024534853A5 (cg-RX-API-DMAC7.html)